title: Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen.
abstract: It was hypothesized that immune recognition could be stimulated with combined immune-based and potent antiviral drug therapies. This study examined human immunodeficiency virus type 1 (HIV-1)-specific lymphocyte proliferation before and after treatment with an inactivated HIV-1 immunogen in 15 chronically infected HIV-1 seropositive subjects. Lymphocyte proliferation to the immunizing antigen (gp120-depleted HIV-1; P<.001), purified native p24 (P<.001), and recombinant p24 (P<.05) increased after treatment with the HIV-specific immune-based therapy. By HIV-1 antigen-specific flow cytometry, T helper CD4 lymphocytes, CD8 lymphocytes, and NK cells (all P<.001) were the predominant cell types proliferating in vitro after treatment. Additional phenotyping of proliferating cells revealed predominantly CD4 and CD8 memory (both P<.001) phenotypes. This study supports the concept that in vitro lymphocyte proliferation to HIV-1 antigens, augmented after treatment with an inactivated HIV-1 immunogen, involves primarily CD4 and CD8 cell memory immune responses.
authors.affiliation: Immune Response Corp., Carlsbad, CA 92008, USA. shotdoc@imnr.com
authors.forename: R B
authors.initials: RB
authors.lastname: Moss
authors.forename: M R
authors.initials: MR
authors.lastname: Wallace
authors.forename: W K
authors.initials: WK
authors.lastname: Giermakowska
authors.forename: E
authors.initials: E
authors.lastname: Webb
authors.forename: J
authors.initials: J
authors.lastname: Savary
authors.forename: C
authors.initials: C
authors.lastname: Chamberlin-Brandt
authors.forename: G
authors.initials: G
authors.lastname: Theofan
authors.forename: R
authors.initials: R
authors.lastname: Musil
authors.forename: S P
authors.initials: SP
authors.lastname: Richieri
authors.forename: F C
authors.initials: FC
authors.lastname: Jensen
authors.forename: D J
authors.initials: DJ
authors.lastname: Carlo
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use; D015703:Antigens, CD / Q000032:analysis; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D004359:Drug Therapy, Combination; D006679:HIV Seropositivity / Q000188:drug therapy / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D007156:Immunologic Memory; D016130:Immunophenotyping; D007694:Killer Cells, Natural / Q000276:immunology; D008213:Lymphocyte Activation; D012044:Regression Analysis; D013601:T-Lymphocytes / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D015164:Vaccines, Inactivated / Q000276:immunology* / Q000627:therapeutic use
chemical_list: D016915:AIDS Vaccines; D019380:Anti-HIV Agents; D015703:Antigens, CD; D015164:Vaccines, Inactivated; C105086:remune